Total Payments
$139,518
2023 Payments
$121.37
Companies
6
Transactions
41
Payment Breakdown by Category
Research$135,924 (97.4%)
Travel$2,544 (1.8%)
Food & Beverage$1,050 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $135,924 | 26 | 97.4% |
| Travel and Lodging | $2,544 | 6 | 1.8% |
| Food and Beverage | $1,050 | 9 | 0.8% |
Payments by Type
Research
$135,924
26 transactions
General
$3,594
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $103,548 | 19 | $0 (2019) |
| Eli Lilly and Company | $32,405 | 8 | $0 (2019) |
| Genentech, Inc. | $1,783 | 3 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $1,614 | 8 | $0 (2018) |
| RxSight Inc | $121.37 | 1 | $0 (2023) |
| Allergan Inc. | $45.51 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $121.37 | 1 | RxSight Inc ($121.37) |
| 2019 | $2,380 | 3 | ACADIA Pharmaceuticals Inc ($1,355) |
| 2018 | $107,660 | 20 | ACADIA Pharmaceuticals Inc ($75,295) |
| 2017 | $29,356 | 17 | ACADIA Pharmaceuticals Inc ($26,899) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/17/2023 | RxSight Inc | RXSIGHT CONTACT LENS (Device), RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE | Food and Beverage | In-kind items and services | $121.37 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/20/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,025.00 | Research |
| Study: A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | ||||||
| 07/16/2019 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $1,304.80 | Research |
| Study: ACP-103-033 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/02/2019 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $49.78 | Research |
| Study: ACP-103-033 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/12/2018 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $250.00 | General |
| 07/12/2018 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $161.74 | General |
| 07/12/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $119.51 | General |
| 06/05/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $11,970.00 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/05/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $2,611.13 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/05/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $1,789.94 | Research |
| Study: ACP-103-033 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/16/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $26,069.67 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/24/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $200.00 | Research |
| Study: ACP-103-032 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/17/2018 | Genentech, Inc. | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $859.22 | General |
| Category: None | ||||||
| 04/17/2018 | Genentech, Inc. | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $527.32 | General |
| Category: None | ||||||
| 04/17/2018 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $396.30 | General |
| Category: None | ||||||
| 04/03/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $49.78 | Research |
| Study: ACP-103-033 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/21/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $2,468.25 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/16/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $9,577.14 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/15/2018 | Eli Lilly and Company | — | — | In-kind items and services | $3.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | ||||||
| 03/07/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $7,779.38 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 02/13/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $20,914.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | ||||||
| 02/13/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $9,071.00 | Research |
| Study: A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | ||||||
| 01/25/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $12,779.38 | Research |
| Study: ACP-103-045 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 01/08/2018 | Eli Lilly and Company | — | — | In-kind items and services | $63.70 | Research |
| Study: A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | ||||||
| 12/21/2017 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $1,922.53 | Research |
| Study: ACP-103-032 • Category: PDP | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-045 | ACADIA Pharmaceuticals Inc | $73,255 | 7 |
| A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | Eli Lilly and Company | $21,754 | 3 |
| ACP-103-032 | ACADIA Pharmaceuticals Inc | $15,924 | 6 |
| ACP-103-033 | ACADIA Pharmaceuticals Inc | $14,369 | 6 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $10,622 | 4 |
About Dr. Mark Ornstein, M.D
Dr. Mark Ornstein, M.D is a Internal Medicine healthcare provider based in Farmingdale, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912089681.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Ornstein, M.D has received a total of $139,518 in payments from pharmaceutical and medical device companies, with $121.37 received in 2023. These payments were reported across 41 transactions from 6 companies. The most common payment nature is "" ($135,924).
Ad
Practice Information
- Specialty Internal Medicine
- Location Farmingdale, NJ
- Active Since 10/20/2006
- Last Updated 04/26/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912089681
Products in Payments
- NUPLAZID (Drug) $103,548
- Non-Covered Product (Drug) $1,783
- CNP520 (Drug) $803.14
- RXSIGHT CONTACT LENS (Device) $121.37
- NAMZARIC (Drug) $45.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Farmingdale
Dr. Orlando Suarez, M.d, M.D
Internal Medicine — Payments: $17,159
Internal Medicine $17,159
Ronald Fagan, M.d, M.D
Internal Medicine — Payments: $15,271
Internal Medicine $15,271
Dr. Azmatullah Hussaini, M.d, M.D
Internal Medicine — Payments: $2,211
Internal Medicine $2,211
Janaya Raynor, Md, MD
Internal Medicine — Payments: $269.25
Internal Medicine $269.25
Claire Kolensky, M.d, M.D
Internal Medicine — Payments: $185.84
Internal Medicine $185.84
Nadeje Sylvester, Md, MD
Internal Medicine — Payments: $62.08
Internal Medicine $62.08